Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa

Table 3 In vitro relaxation of phenylephrine-pre-contracted corpora cavernosa from normal (control) or diabetic rabbits by SAR407899 and sildenafil: effect of the NO synthase inhibitor L-NAME (0.3 mM)

	RELAXATION OF RABBIT CORPUS CAVERNOSUM IC₅₀, μM (95% confidence interval) %Emax ± SEM
	Controls		Diabetes
	---	L-NAME	---	L-NAME
SAR407899	0.40	0.28 **	0.42 ##	0.42 ^○○
	(0.23-0.69)	(0.13-0.60)	(0.20-0.90)	(0.14-1.26)
	95 ± 1.4§	93 ± 2.3***	95 ± 1.4###	96 ± 1.4^○○○
SILDENAFIL	0.22	1.13	1.45	1.47
	(0.11-0.45)	(0.35-3.66)	(0.27-7.81)	(1.01-2.14)
	83 ± 2.3	65 ± 9.9	65 ± 9.6	45 ± 5.3

Maximal effect is expressed as a percentage of the relaxation induced by 0.1 mM papaverine. Results were analyzed by three-way ANOVA + Winer analysis. Significance of differences between groups: § p < 0.05 vs. sildenafil control (-L-NAME); ** 0.001 < p < 0.01 vs. sildenafil control (+L-NAME); ***p < 0.001 vs. sildenafil control (+L-NAME); ## 0.001 < p < 0.01 vs. sildenafil control (-L-NAME); ### p < 0.001 vs. sildenafil control (-L-NAME); ○○ 0.001 < p < 0.01 vs. sildenafil diabetic (+L-NAME); ○○○p < 0.001 vs. sildenafil diabetic (+L-NAME)

ISSN: 1479-5876